| __timestamp | Genmab A/S | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 22570000 |
| Thursday, January 1, 2015 | 91224000 | 24378000 |
| Friday, January 1, 2016 | 102413000 | 26621000 |
| Sunday, January 1, 2017 | 146987000 | 28653000 |
| Monday, January 1, 2018 | 213695000 | 37734000 |
| Tuesday, January 1, 2019 | 342000000 | 41884000 |
| Wednesday, January 1, 2020 | 661000000 | 64435000 |
| Friday, January 1, 2021 | 1283000000 | 57483000 |
| Saturday, January 1, 2022 | 2676000000 | 70062000 |
| Sunday, January 1, 2023 | 3297000000 | 52790000 |
| Monday, January 1, 2024 | 3790000000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology, effective cost management is crucial. Over the past decade, Genmab A/S and Ligand Pharmaceuticals Incorporated have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Genmab A/S saw a staggering increase of over 4,000% in SG&A expenses, peaking at approximately $3.3 billion in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, Ligand Pharmaceuticals maintained a more conservative approach, with expenses growing by about 130% over the same period, reaching around $70 million in 2022. This strategic restraint highlights their focus on maintaining lean operations. As the biotech industry continues to grow, these insights into SG&A management offer valuable lessons for companies aiming to balance growth with cost efficiency.
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Genmab A/S
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Biogen Inc. and Ligand Pharmaceuticals Incorporated
BeiGene, Ltd. and Genmab A/S: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Genmab A/S vs Madrigal Pharmaceuticals, Inc.
Genmab A/S and Pharming Group N.V.: SG&A Spending Patterns Compared
Genmab A/S or Jazz Pharmaceuticals plc: Who Manages SG&A Costs Better?
Genmab A/S and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Genmab A/S or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Genmab A/S and Protagonist Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Amicus Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated